Buoni Sabrina, Zannolli Raffaella, Sorrentino Livio, Fois Alberto
Department of Pediatrics, University of Siena, Siena, Italy.
Arch Neurol. 2006 Oct;63(10):1479-82. doi: 10.1001/archneur.63.10.1479.
To our knowledge, there have been no reports on the control of central nervous system symptoms in patients with ataxia-telangiectasia.
To preliminarily determine the effectiveness of corticosteroid therapy on the central nervous system symptoms of a child with ataxia-telangiectasia in whom neurological signs improved when, occasionally, he was given betamethasone to treat asthmatic bronchitis attacks.
Case report.
Tertiary care hospital. Patient A 3-year-old boy with the classic hallmarks and a proved molecular diagnosis of ataxia-telangiectasia.
We used betamethasone, 0.1 mg/kg per 24 hours, divided every 12 hours, for 4 weeks to preliminarily determine its effectiveness on the child's central nervous system symptoms and its safety. Methylprednisolone, 2 mg/kg per 24 hours, divided every 12 hours, was then given in an attempt to perform a long-term treatment.
There were improvements in the child's neurological symptoms 2 or 3 days after the beginning of the drug treatment. After 2 weeks of treatment, the improvement was dramatic: the disturbance of stance and gait was clearly reduced, and the control of the head and neck had increased, as had control of skilled movements. At 4 weeks of treatment, adverse effects mainly included increased appetite and body weight and moon face. No beneficial effect was obtained when, after 4 weeks, betamethasone was replaced with methylprednisolone. Six months later, without therapy, the child continued to experience severe signs of central nervous system impairment.
Controlled studies to better understand the most appropriate drug and therapeutic schedule are required.
据我们所知,尚无关于共济失调毛细血管扩张症患者中枢神经系统症状控制的报道。
初步确定皮质类固醇疗法对一名共济失调毛细血管扩张症患儿中枢神经系统症状的有效性,该患儿在偶尔接受倍他米松治疗哮喘性支气管炎发作时神经体征有所改善。
病例报告。
三级护理医院。患者为一名3岁男孩,具有典型特征且经分子诊断确诊为共济失调毛细血管扩张症。
我们使用倍他米松,每24小时0.1毫克/千克,每12小时分一次,共4周,以初步确定其对患儿中枢神经系统症状的有效性及其安全性。然后给予甲泼尼龙,每24小时2毫克/千克,每12小时分一次,试图进行长期治疗。
药物治疗开始后2或3天,患儿的神经症状有所改善。治疗2周后,改善显著:姿势和步态障碍明显减轻,头部和颈部的控制能力增强,熟练动作的控制能力也增强。治疗4周时,不良反应主要包括食欲增加、体重增加和满月脸。4周后用甲泼尼龙替代倍他米松未获得有益效果。6个月后,未经治疗,患儿继续出现严重的中枢神经系统损害体征。
需要进行对照研究以更好地了解最合适的药物和治疗方案。